ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Pooled it
- Recent Advances in Two-Photon-Activatable Metal Complexes for Photodynamic Therapy.Angewandte Chemie (International ed. in English) · 2026Review
- Endoluminal photodynamic therapy with a photoreactive stent-based catheter system to treat malignant colorectal obstruction.Bioengineering & translational medicine · 2025Article
- Photodynamic therapy for the precise treatment of localized prostate cancer.Frontiers in oncology · 2025Review
- Spectroscopic and Computational pH Study of NiMolecules (Basel, Switzerland) · 2023Article
- Porphyrin Macrocycles: General Properties and Theranostic Potential.Molecules (Basel, Switzerland) · 2023Review
- Theranostics with photodynamic therapy for personalized medicine: to see and to treat.Theranostics · 2023Review
- Comparative Analysis of Tetra(2-naphthyl)tetracyano-porphyrazine and Its Iron Complex as Photosensitizers for Anticancer Photodynamic Therapy.Pharmaceutics · 2022Article
- Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges.Journal of nanobiotechnology · 2022Review
- Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Frontiers in oncology · 2022Review
- Phototherapy Combined with Carbon Nanomaterials (1D and 2D) and their Applications in Cancer Therapy.Materials (Basel, Switzerland) · 2020Review
- 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy.Scientific reports · 2020Article
- Photodynamic Therapy for Cancer: What's Past is Prologue.Photochemistry and photobiology · 2020Review
- Review
- Validation of combined Monte Carlo and photokinetic simulations for the outcome correlation analysis of benzoporphyrin derivative-mediated photodynamic therapy on mice.Journal of biomedical optics · 2019Article
- Near Infrared Photoimmunotherapy with Combined Exposure of External and Interstitial Light Sources.Molecular pharmaceutics · 2018Article
- Clinical development of photodynamic agents and therapeutic applications.Biomaterials research · 2018Review
- Porphyrin-grafted Lipid Microbubbles for the Enhanced Efficacy of Photodynamic Therapy in Prostate Cancer through Ultrasound-controlledTheranostics · 2018Article
- Photosensitizers in prostate cancer therapy.Oncotarget · 2017Review
- Interstitial Photodynamic Therapy-A Focused Review.Cancers · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe time course of serum prostate-specific antigen (PSA) response to photodynamic therapy (PDT) of prostate cancer was measured. EXPERIMENTAL
designSeventeen patients were treated in a phase I trial of motexafin lutetium-PDT. PDT dose was calculated in each patient as the product of the ex vivo measured pre-PDT photosensitizer level and the in situ measured light dose. Serum PSA level was measured within 2 months before PDT (baseline), and at day 1; weeks 1 to 3; months 1, 2, and 3; months 4 to 6; and months 7 to 11 after PDT.
resultsAt 24 hours after PDT, serum PSA increased by 98% +/- 36% (mean +/- SE) relative to baseline levels (P = 0.007). When patients were dichotomized based on median PDT dose, those who received high PDT dose showed a 119% +/- 52% increase in PSA compared with a 54% +/- 27% increase in patients treated at low PDT dose. Patients treated with high versus low PDT dose showed a median biochemical delay of 82 versus 43 days (P = 0.024), with biochemical delay defined as the length of time between PDT and a nonreversible increase in PSA to a value greater than or equal to baseline.
conclusionsResults show PDT to induce large, transient increases in serum PSA levels. Patients who experienced high PDT dose showed greater short-term increase in PSA and a significantly more durable PSA response (biochemical delay). These data strongly promote the need for individualized delivery of PDT dose and assessment of treatment effect in PDT of prostate cancer. Information gained from such patient-specific measurements could facilitate the introduction of multiple PDT sessions in patients who would benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.